Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancer-A Multi-Institutional Study

被引:13
|
作者
Stoen, Maria J. [1 ]
Andersen, Sigve [2 ,3 ]
Rakaee, Mehrdad [2 ,4 ]
Pedersen, Mona, I [2 ]
Ingebriktsen, Lise M. [1 ,5 ]
Donnem, Tom [2 ,3 ]
Lombardi, Ana P. G. [1 ]
Kilvaer, Thomas K. [1 ,3 ]
Busund, Lill-Tove R. [1 ,6 ]
Richardsen, Elin [1 ,6 ]
机构
[1] UiT Arctic Univ Norway, Inst Med Biol, Translat Canc Res Grp, N-9037 Tromso, Norway
[2] UiT Arctic Univ Norway, Inst Clin Med, Translat Canc Res Grp, N-9037 Tromso, Norway
[3] Univ Hosp North Norway, Dept Oncol, N-9038 Tromso, Norway
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[5] Univ Bergen, Ctr Canc Biomarkers CCBIO, Dept Clin Med, Sect Pathol, N-5021 Bergen, Norway
[6] Univ Hosp North Norway, Dept Clin Pathol, N-9038 Tromso, Norway
关键词
prostate cancer; microRNA; miR-20a-5p; radical prostatectomy; biomarker; prognostication; CIRCULATING MICRORNAS; EXPRESSION; CLUSTER; PROGRESSION; PREDICTION; BIOMARKERS; DIAGNOSIS; MIR-17-92; GENOMICS; PROPOSAL;
D O I
10.3390/cancers13164096
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary MicroRNAs (miRs) have critical regulatory roles in cell functions, and are involved in prostate cancer tumorigenesis. miR-20a-5p is a member of the oncogenic miR-17-92 cluster. Overexpressed miR-20a-5p has been shown to increase both cell proliferation and cell migration in cancers. The aim of our cohort study was to evaluate the prognostic role of miR-20a-5p in prostate cancer. We found miR-20a-5p associated with biochemical failure in tumor epithelium and tumor stroma. In the multivariable analysis miR-20a-5p in tumor epithelium was found to be an independent prognostic predictor for biochemical failure. In the functional studies, migration and invasion were significantly increased in miR-20a-5p transfected prostate cancer cell lines. In conclusion, high miR-20a-5p expression in tumor epithelium is a negative independent prognostic factor for biochemical failure in prostate cancer. Objective: assessing the prognostic role of miR-20a-5p, in terms of clinical outcome, in a large multi-institutional cohort study. Methods: Tissue microarrays from 535 patients' prostatectomy specimens were constructed. In situ hybridization was performed to assess the expression level of miR-20a-5p in different tissue subregions: tumor stroma (TS) and tumor epithelium (TE). In vitro analysis was performed on prostate cancer cell lines. Results: A high miR-20a-5p expression was found negatively in association with biochemical failure in TE, TS and TE + TS (p = 0.001, p = 0.003 and p = 0.001, respectively). Multivariable analysis confirmed that high miR-20a-5p expression in TE independently predicts dismal prognosis for biochemical failure (HR = 1.56, 95% CI: 1.10-2.21, p = 0.014). Both DU145 and PC3 cells exhibited increased migration ability after transient overexpression of miR-20a-5p, as well as significant elevation of invasion in DU145 cells. Conclusion: A high miR-20a-5p expression in tumor epithelium is an independent negative predictor for biochemical prostate cancer recurrence.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Significantly altered expression of miR-5-11-3p and its target AKT3 has negative prognostic value in human prostate cancer
    Zhang, Fan
    Wu, Zhongjun
    BIOCHIMIE, 2017, 140 : 66 - 72
  • [42] PREDICTING PROSTATE CANCER-SPECIFIC OUTCOME AMONG MEN WITH PSA ≥20 ng/ml AND MULTIPLE UNFAVOURABLE RISK FACTORS: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 712 PATIENTS
    Spahn, M.
    Gontero, P.
    Joniau, S.
    Marchioro, G.
    Fieuws, S.
    Tombal, B.
    Kneitz, B.
    Hsu, C. Y.
    Van Der Eeckt, K.
    Bader, P.
    Frohneberg, D.
    Frea, B.
    Terrone, C.
    Tizzani, A.
    Van Poppel, H.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1439 - 1439
  • [43] Tumor architecture is an independent prognostic factor for disease relapse and cancer-specific survival in patients treated with nephroureterectomy: A multi-institutional analysis of 1363 patients from the upper tract urothelial carcinoma collaboration
    Remzi, Mesut
    Waldert, Matthias
    Margulis, Vitally
    Montorsi, Francesco
    Kikuchi, Eiji
    Zigeuner, Richard
    Weizer, Alon Z.
    Bolenz, Christian
    Mikami, Shuji
    Lotan, Yair
    Koppie, Theresa M.
    Ng, Casey K.
    Fernandez, Mario
    Suardi, Nazareno
    Bensalah, Karim
    Phillip, Stroebel
    Roscigno, Marco
    Akhtar, Mohammed
    Guo, Charles C.
    Wood, Christipher G.
    Bertini, Roberto
    Kosaka, Takeo
    Kabbani, Wareef
    Karakiewicz, Pierre I.
    Shariat, Shahrokh F.
    JOURNAL OF UROLOGY, 2008, 179 (04): : 72 - 72
  • [44] Cancer cell-derived exosomal miR-20a-5p inhibits CD8+ T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer
    Li, Weina
    Han, Guohui
    Li, Feng
    Bu, Peng
    Hao, Yating
    Huang, Li
    Bai, Xiangdong
    CANCER SCIENCE, 2024, 115 (02) : 347 - 356
  • [45] Can Pelvic Lymph Node Dissection in Prostate Cancer Patients with a 5% Briganti Nomogram Cut-off Value Provide an Oncological Benefit? A Large Multi-Institutional Cohort Study in Japan
    Sugihara, Naoya
    Hashine, Katsuyoshi
    Yamashita, Natsumi
    Sakamoto, Miki
    Terashita, Masato
    Funaki, Keisuke
    Saiki, Kaori
    Sawada, Takatora
    Kakuda, Toshio
    Nishimura, Kenichi
    Fukumoto, Tetsuya
    Miura, Noriyosi
    Miyauchi, Yuki
    Kikugawa, Tadahiko
    Saika, Takashi
    ACTA MEDICA OKAYAMA, 2024, 78 (04) : 307 - 312
  • [46] PREDICTING PROSTATE CANCER SPECIFIC OUTCOME AFTER RADICAL PROSTATECTOMY AMONG MEN WITH PSA &[GE] 20 NG/ML WITH OR WITHOUT ADDITIONAL HIGH RISK FACTORS: A MULTI-INSTITUTIONAL OUTCOME STUDY OF 712 PATIENTS
    Spahn, Martin
    Gontero, Paolo
    Kneitz, Burkhard
    Tombal, Bertrand
    Hsu, Belgium C-J
    Van der Eeckt, Kathie
    Marchioro, Giansilvio
    Bader, Pia
    Frohneberg, Detlef
    Van Poppel, Hein
    Joniau, Steven
    JOURNAL OF UROLOGY, 2010, 183 (04): : E227 - E227
  • [47] Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12
    Lee, Jong Hoon
    Kim, Nae Yong
    Kim, Sung Hwan
    Cho, Hyeon Min
    Shim, Byoung Yong
    Kim, Tae Hyun
    Kim, Sun Young
    Baek, Ji Yeon
    Oh, Jae Hwan
    Nam, Taek Keun
    Yoon, Mee Sun
    Jeong, Jae Uk
    Kim, Kyubo
    Chie, Eui Kyu
    Jang, Hong Seok
    Kim, Jae-Sung
    Kim, Jin Hee
    Jeong, Bae Kwon
    RADIOTHERAPY AND ONCOLOGY, 2015, 116 (02) : 202 - 208
  • [48] Long-term oncologic outcomes of robot-assisted versus open radical prostatectomy for prostate cancer with seminal vesicle invasion: a multi-institutional study with a minimum 5-year follow-up
    Jungyo Suh
    In Gab Jeong
    Hwang Gyun Jeon
    Chang Wook Jeong
    Sangchul Lee
    Seong Soo Jeon
    Seok Soo Byun
    Cheol Kwak
    Hanjong Ahn
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1951 - 1960
  • [49] Long-term oncologic outcomes of robot-assisted versus open radical prostatectomy for prostate cancer with seminal vesicle invasion: a multi-institutional study with a minimum 5-year follow-up
    Suh, Jungyo
    Jeong, In Gab
    Jeon, Hwang Gyun
    Jeong, Chang Wook
    Lee, Sangchul
    Jeon, Seong Soo
    Byun, Seok Soo
    Kwak, Cheol
    Ahn, Hanjong
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1951 - 1960
  • [50] Clinical qualification of plasma androgen receptor (pAR) status and outcome on abiraterone acetate (AA) plus prednisone or dexamethasone ( plus P/D) in a phase II multi-institutional study in metastatic castration resistant prostate cancer (mCRPC).
    Jayaram, Anuradha
    Wingate, Anna
    Sharabiani, Mansour Taghavi Azar
    Wetterskog, Daniel
    Calabro, Fabio
    Barwell, Lorraine
    Arlt, Weibke
    Merseburger, Axel Stuart
    Feyerabend, Susan
    Berruti, Alfredo
    Lefresne, Florence
    Shen, Dong
    Gormley, Michael
    Kapoor, Gurpreet
    Li, Weimin
    Jones, Robert J.
    Sternberg, Cora N.
    Tombal, Bertrand F.
    Attard, Gerhardt
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)